Mivtachim The Workers Social Insurance Fund LTD Lowered Its Teva Pharmaceutical Inds LTD (TEVA) Holding by $4.76 Million

June 21, 2018 - By Peter Erickson

Teva Pharmaceutical Industries Limited (NYSE:TEVA) Logo

Mivtachim The Workers Social Insurance Fund Ltd decreased its stake in Teva Pharmaceutical Inds Ltd (TEVA) by 28.57% based on its latest 2018Q1 regulatory filing with the SEC. Mivtachim The Workers Social Insurance Fund Ltd sold 280,000 shares as the company’s stock rose 10.90% while stock markets declined. The institutional investor held 700,000 shares of the major pharmaceuticals company at the end of 2018Q1, valued at $11.96M, down from 980,000 at the end of the previous reported quarter. Mivtachim The Workers Social Insurance Fund Ltd who had been investing in Teva Pharmaceutical Inds Ltd for a number of months, seems to be less bullish one the $24.73 billion market cap company. The stock increased 0.96% or $0.23 during the last trading session, reaching $24.28. About 7.93 million shares traded. Teva Pharmaceutical Industries Limited (NYSE:TEVA) has declined 22.74% since June 21, 2017 and is downtrending. It has underperformed by 35.31% the S&P500.

Mivtachim The Workers Social Insurance Fund Ltd, which manages about $1.42 billion US Long portfolio, upped its stake in Financial Select Sector Spdr (XLF) by 1.00M shares to 3.24 million shares, valued at $89.43M in 2018Q1, according to the filing.

Analysts await Teva Pharmaceutical Industries Limited (NYSE:TEVA) to report earnings on August, 2. They expect $0.62 EPS, down 37.37 % or $0.37 from last year’s $0.99 per share. TEVA’s profit will be $631.47M for 9.79 P/E if the $0.62 EPS becomes a reality. After $0.91 actual EPS reported by Teva Pharmaceutical Industries Limited for the previous quarter, Wall Street now forecasts -31.87 % negative EPS growth.

More notable recent Teva Pharmaceutical Industries Limited (NYSE:TEVA) news were published by: Seekingalpha.com which released: “Premarket analyst action – healthcare” on June 18, 2018, also Globes.Co.Il with their article: “Mon: Teva rises strongly as TASE falls” published on June 18, 2018, Seekingalpha.com published: “Bear case on Teva weakens further?” on June 18, 2018. More interesting news about Teva Pharmaceutical Industries Limited (NYSE:TEVA) were released by: Globes.Co.Il and their article: “Tue: Teva rally fails to lift TASE” published on June 12, 2018 as well as Streetinsider.com‘s news article titled: “Morgan Stanley Remains Sidelined on Teva Pharma (TEVA) Following Study” with publication date: June 18, 2018.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) Ratings Coverage

Among 20 analysts covering Teva Pharma (NYSE:TEVA), 5 have Buy rating, 3 Sell and 12 Hold. Therefore 25% are positive. Teva Pharma has $2700 highest and $13.0 lowest target. $19.46’s average target is -19.85% below currents $24.28 stock price. Teva Pharma had 37 analyst reports since December 22, 2017 according to SRatingsIntel. RBC Capital Markets maintained Teva Pharmaceutical Industries Limited (NYSE:TEVA) on Tuesday, January 30 with “Sell” rating. The rating was maintained by Guggenheim on Tuesday, January 16 with “Hold”. The rating was maintained by BTIG Research on Monday, February 12 with “Sell”. The rating was maintained by Leerink Swann with “Underperform” on Friday, February 9. The stock of Teva Pharmaceutical Industries Limited (NYSE:TEVA) earned “Buy” rating by Mizuho on Friday, April 20. The stock of Teva Pharmaceutical Industries Limited (NYSE:TEVA) has “Equal-Weight” rating given on Monday, May 7 by Morgan Stanley. Guggenheim maintained the stock with “Hold” rating in Tuesday, March 13 report. On Thursday, January 18 the stock rating was downgraded by BTIG Research to “Neutral”. The stock of Teva Pharmaceutical Industries Limited (NYSE:TEVA) earned “Hold” rating by RBC Capital Markets on Friday, February 9. The stock of Teva Pharmaceutical Industries Limited (NYSE:TEVA) has “Sell” rating given on Tuesday, January 2 by Leerink Swann.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: